share_log

8-K: Ginkgo Bioworks Reports Third Quarter 2024 Financial Results

8-K: Ginkgo Bioworks Reports Third Quarter 2024 Financial Results

8-K：Ginkgo Bioworks公布2024年第三季度财务业绩
美股SEC公告 ·  2024/11/13 06:09

Moomoo AI 已提取核心信息

Ginkgo Bioworks reported Q3 2024 revenue of $89 million, up 61% YoY, primarily driven by a $45 million non-cash deferred revenue release. Excluding this impact, revenue was $44 million, down 21% YoY. Cell Engineering revenue decreased 20% to $30 million while Biosecurity revenue fell to $14 million. The company posted a loss from operations of $55 million, improved from $286 million loss in Q3 2023.The company made significant progress on its restructuring plan, targeting over $85 million in annualized savings by mid-2025 through workforce reductions and site consolidation initiatives. Ginkgo signed new deals with Novo Nordisk and achieved a major research milestone with Merck, expected to generate $9 million in Q4 2024.Dr. Sri Kosuri, CEO of Octant, joined the Board as a Class B director on November 6, while Dr. Arie Belldegrun resigned after serving since September 2021. The company updated its 2024 guidance to reflect the deferred revenue impact, now expecting total revenue of $215-235 million, including Cell Engineering revenue of $165-185 million and Biosecurity revenue of at least $50 million.
Ginkgo Bioworks reported Q3 2024 revenue of $89 million, up 61% YoY, primarily driven by a $45 million non-cash deferred revenue release. Excluding this impact, revenue was $44 million, down 21% YoY. Cell Engineering revenue decreased 20% to $30 million while Biosecurity revenue fell to $14 million. The company posted a loss from operations of $55 million, improved from $286 million loss in Q3 2023.The company made significant progress on its restructuring plan, targeting over $85 million in annualized savings by mid-2025 through workforce reductions and site consolidation initiatives. Ginkgo signed new deals with Novo Nordisk and achieved a major research milestone with Merck, expected to generate $9 million in Q4 2024.Dr. Sri Kosuri, CEO of Octant, joined the Board as a Class B director on November 6, while Dr. Arie Belldegrun resigned after serving since September 2021. The company updated its 2024 guidance to reflect the deferred revenue impact, now expecting total revenue of $215-235 million, including Cell Engineering revenue of $165-185 million and Biosecurity revenue of at least $50 million.
Ginkgo Bioworks报告2024年第三季度营业收入为8900万美元，同比上升61%，主要是由于4500万美元的非现金递延营业收入释放。排除这一影响，营业收入为4400万美元，同比下降21%。电芯工程营业收入下降20%，为3000万美元，生物安全营业收入降至1400万美元。该公司报告运营亏损为5500万美元，较2023年第三季度的28600万美元亏损有所改善。该公司在其重组计划上取得了显著进展，预计到2025年中期通过裁员和场地整合措施实现超过8500万美元的年度节省。Ginkgo与诺和诺德签署了新协议，并与默沙东达成了重大研究里程碑，预计将在2024年第四季度产生900万美元的收入。展开全部
Ginkgo Bioworks报告2024年第三季度营业收入为8900万美元，同比上升61%，主要是由于4500万美元的非现金递延营业收入释放。排除这一影响，营业收入为4400万美元，同比下降21%。电芯工程营业收入下降20%，为3000万美元，生物安全营业收入降至1400万美元。该公司报告运营亏损为5500万美元，较2023年第三季度的28600万美元亏损有所改善。该公司在其重组计划上取得了显著进展，预计到2025年中期通过裁员和场地整合措施实现超过8500万美元的年度节省。Ginkgo与诺和诺德签署了新协议，并与默沙东达成了重大研究里程碑，预计将在2024年第四季度产生900万美元的收入。Octant的首席执行官Sri Kosuri博士于11月6日加入董事会，担任B类董事，而自2021年9月以来服务的Arie Belldegrun博士辞职。该公司更新了2024年的指导，以反映递延收入的影响，现预计总营业收入在21500万至23500万之间，包括电芯工程营业收入在16500万至18500万之间，以及生物安全营业收入至少5000万美元。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间